Armand de Gramont
Overview
Explore the profile of Armand de Gramont including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
1398
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Evrard D, Dumont C, Gatineau M, Delord J, Fayette J, Dreyer C, et al.
Cancers (Basel)
. 2022 Sep;
14(18).
PMID: 36139669
Mammalian target of rapamycin (mTOR) regulates cellular functions by integrating intracellular signals and signals from the tumor microenvironment (TME). The PI3K-AKT-mTOR pathway is activated in 70% of head and neck...
2.
Bentayeb H, Aitamer M, Petit B, Dubanet L, Elderwish S, Desaubry L, et al.
J Exp Clin Cancer Res
. 2019 Nov;
38(1):450.
PMID: 31684984
Background: Diffuse large B-cell lymphomas (DLBCLs) are aggressive lymphomas accounting for approximately a third of non-Hodgkin lymphomas. Prohibitin 1 (PHB1) and prohibitin 2 (PHB2) are scaffold proteins that promote mitochondria...
3.
Szturz P, Budikova M, Vermorken J, Horova I, Gal B, Raymond E, et al.
Oral Oncol
. 2017 Nov;
74:68-76.
PMID: 29103754
Objectives: The hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (c-MET) ligand/receptor axis has been implicated in pathogenesis of malignant diseases including squamous cell carcinoma of the head and neck (SCCHN). Overexpression...
4.
de Gramont A, Faivre S, Raymond E
Oncoimmunology
. 2017 Feb;
6(1):e1257453.
PMID: 28197376
Transforming Growth Factor (TGF)-β inhibitors have been in development for decades with the outmost results of being promising candidates. From the latest clinical results at the 2016 ASCO meeting converging...
5.
de Gramont A, Herrera A, De Gramont A
N Engl J Med
. 2017 Jan;
376(3):288-289.
PMID: 28102649
No abstract available.
6.
Bouattour M, Soubrane O, de Gramont A, Faivre S
Trials
. 2016 Nov;
17(1):563.
PMID: 27887632
Trial Registration: ClinicalTrials.gov: NCT00692770 . Registered 5 June 2008. This study has been completed.
7.
Serova M, Tijeras-Raballand A, Dos Santos C, Martinet M, Neuzillet C, Lopez A, et al.
Oncotarget
. 2016 Aug;
7(25):38467-86.
PMID: 27509260
Angiogenesis is hallmark of clear cell renal cell carcinogenesis. Anti-angiogenic therapies have been successful in improving disease outcome; however, most patients treated with anti-angiogenic agents will eventually progress. In this...
8.
Sebbagh S, Roux J, Dreyer C, Neuzillet C, de Gramont A, Orbegoso C, et al.
Acta Oncol
. 2016 Jun;
55(9-10):1168-1174.
PMID: 27333436
Background: Gemcitabine (GEM)-platinum chemotherapy stands as first-line therapy for patients with recurrent/advanced biliary tract cancer (BTC), yielding progression-free survival (PFS) of 3.4-6.4 months. No standard second-line chemotherapy after GEM-platinum failure...
9.
Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?
Faivre S, de Gramont A, Raymond E
Target Oncol
. 2016 Mar;
11(4):565-7.
PMID: 26996978
No abstract available.
10.
Andre T, de Gramont A, Vernerey D, Chibaudel B, Bonnetain F, Tijeras-Raballand A, et al.
J Clin Oncol
. 2015 Nov;
33(35):4176-87.
PMID: 26527776
Purpose: The MOSAIC (Multicenter International Study of Oxaliplatin/Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer) study has demonstrated 3-year disease-free survival (DFS) and 6-year overall survival (OS) benefit of adjuvant...